Fortuna Papa
University of Naples Federico II
5 Papers
20 Citations
Fortuna Papa is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Internal medicine & Everolimus. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center.
Chiara Simeoli,Rosario Ferrigno,M. C. De Martino,Davide Iacuaniello,Fortuna Papa,D. Angellotti,Claudia Pivonello,Roberta Patalano,Mariarosaria Negri,A. Colao,Rosario Pivonello +10 more
TL;DR: It is confirmed that pasireotide may be considered a valid option for treatment of patients with Cushing’s disease, although it requires an appropriate management of adverse events, especially hyperglycaemia.
The role of mTOR pathway as target for treatment in adrenocortical cancer.
Maria Cristina De Martino,Richard A Feelders,Claudia Pivonello,Chiara Simeoli,Fortuna Papa,Annamaria Colao,Rosario Pivonello,Leo J. Hofland +7 more
TL;DR: The mTOR pathway seems a potential target for treatment of patients with ACC, but further investigation is still required to define the potential role of mTOR inhibitors alone or in combination with other drugs in the treatment of ACC patients.
GH deficiency in cancer survivors in the transition age: diagnosis and therapy.
Emilia Sbardella,Marco Crocco,Tiziana Feola,Fortuna Papa,Giulia Puliani,Daniele Gianfrilli,Andrea M. Isidori,Ashley B. Grossman +7 more
TL;DR: Endocrine dysfunction among CCSs has a high prevalence in the transition age and increase with time, and it is crucial that transition specialized clinics should be increased in terms of number and specific skills in order to manage endocrine disorders in adolescence, a delicate and complex period of life.
8
mTOR Inhibitor Use Is Associated With a Favorable Outcome of COVID-19 in Patients of Kidney Transplant: Results of a Retrospective Study
Biagio Pinchera,Lorenzo Spirito,Antonio Riccardo Buonomo,Maria Foggia,Rosa Carrano,Fabrizio Salemi,Elisa Schettino,Fortuna Papa,Roberto La Rocca,Felice Crocetto,Luigi Napolitano,R. Villari,Ivan Gentile +12 more
TL;DR: Patients who received mTOR inhibitors, as part of their immunosuppressive therapy, compared to other regimens had a lower chance of developing a moderate or severe form of the disease (OR = 0.8, 95, CI: (0.21–0.92), P =0.041).
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit.
Donatella Paola Provvisiero,Mariarosaria Negri,Cristina de Angelis,Gilda Di Gennaro,Roberta Patalano,Chiara Simeoli,Fortuna Papa,Rosario Ferrigno,Renata S. Auriemma,Maria Cristina De Martino,Annamaria Colao,Rosario Pivonello,Claudia Pivonello +12 more
TL;DR: It is demonstrated that VitD can re-sensitize HCC cells resistant to EVE treatment triggering miR-375 up-regulation and consequently down-regulating several oncogenes responsible of EMT and drug resistance.